<?xml version="1.0" encoding="UTF-8"?>
<p id="JVEv5-para-0155">Promising proof of concept from the first HIV-1 
 <italic>gag</italic>-specific ImmTAV was presented showing activity at low effector-to-target ratios when tested 
 <italic>ex vivo</italic> with CD4 T cells from HIV-1 positive patients on ART 
 <xref rid="JVEv5-bib-0068" ref-type="bibr">[68,69]</xref>. Additional work will, however, be necessary to define the levels of viral antigen expression required in the reservoir for the approach to be effective, and evaluate whether the technology can indeed be translated across HLA types and assess potential toxicity.
</p>
